Are you Dr. Adewoye?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 22 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
732 Harrison Ave
Preston-3
Boston, MA 02118Phone+1 617-638-6428- Is this information wrong?
Summary
- Dr. Adeboye Adewoye, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in California.
Education & Training
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Meharry Medical CollegeResidency, Internal Medicine, 1996 - 1999
University of Jos Faculty of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 2004 - 2025
Publications & Presentations
PubMed
- 13 citationsEvaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.Jacob D. Soumerai, Ai Ni, Guan Xing, Julie Huang, Richard R. Furman, Jeffrey A. Jones, Jeffrey P. Sharman, Michael Hallek, Adeboye H. Adewoye, Ronald L. Dubowy, Lyndah...> ;Leukemia & Lymphoma. 2019 May 12
- 18 citationsFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignanciesArnon P. Kater, Sanne H. Tonino, Marjolein Spiering, Martine E.D. Chamuleau, Roberto D. Liu, Adeboye H. Adewoye, Jie Gao, Lyndah Dreiling, Yan Xin, Jeanette K. Doordui...> ;Blood Cancer Journal. 2018 Feb 12
- 172 citationsIdelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phas...Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklos Egyed, Paolo Ghia, Árpád Illés, Wojciech Jurczak, Paula Marlt...> ;The Lancet. Oncology. 2017 Mar 1
- Join now to see all
Grant Support
- Vitamin D Supplementation And Bone Changes In Sickle Cell DiseaseNational Center For Research Resources2006–2007
